Similar Search Results

The Chinese Pharmaceutical Market at the Crossroads: Pro-Competition Solutions to Improve Access, Quality and Affordability

Wang, Y. Richard - In: Applied Health Economics and Health Policy 4 (2005) 3, pp. 147-151

The Chinese pharmaceutical market is large in absolute size (the second largest in Asia), but it faces similar problems to those that plague other developing countries, such as a lack of adequate patent protection, low pharmaceutical spending per capita, but high pharmaceutical expenditure as a...

Persistent link: https://www.econbiz.de/10005448954

Germany's Decision Rule for Setting Ceiling Prices of Drugs: A Comparative Analysis with Other Decision Rules

Gandjour, Afschin - In: Applied Health Economics and Health Policy 9 (2011) 2, pp. 65-71

In Germany, the Institute for Quality and Efficiency in Health Care (IQWiG) makes recommendations for ceiling prices of drugs based on an evaluation of the relationship between costs and effectiveness. To set ceiling prices, IQWiG uses the following decision rule: the incremental...

Persistent link: https://www.econbiz.de/10010614262

The Economics of the NHS Cancer Drugs Fund

Maynard, Alan; Bloor, Karen - In: Applied Health Economics and Health Policy 9 (2011) 3, pp. 137-138

Persistent link: https://www.econbiz.de/10010614264

To Retain or Remove User Fees?: Reflections on the Current Debate in Low- and Middle-Income Countries

James, Chris D.; Hanson, Kara; McPake, Barbara; … - In: Applied Health Economics and Health Policy 5 (2006) 3, pp. 137-153

Many low- and middle-income countries continue to search for better ways of financing their health systems. Common to many of these systems are problems of inadequate resource mobilisation, as well as inefficient and inequitable use of existing resources. The poor and other vulnerable groups who...

Persistent link: https://www.econbiz.de/10005448953

Community-Based Youth Tobacco Control Interventions: Cost Effectiveness of the Full Court Press Project

Ross, Hana; Powell, Lisa M.; Bauer, Joseph E.; Levy, … - In: Applied Health Economics and Health Policy 5 (2006) 3, pp. 167-176

Background: We evaluated the impact of a community-based tobacco control project that was implemented in the city of Tucson, Arizona, USA, between 1996 and 2001. Aim: The project's goal was to reduce the prevalence of youth smoking through change in social norms at schools and in communities and...

Persistent link: https://www.econbiz.de/10005448960

Centralising Drug Review to Improve Coverage Decisions: Economic Lessons From (and For) Canada

Morgan, Steve; McMahon, Meghan; Mitton, Craig - In: Applied Health Economics and Health Policy 5 (2006) 2, pp. 67-73

Drug coverage decisions require information about clinically relevant benefits and risks, as well as economic information about direct and indirect costs, in comparison with relevant treatment alternatives. A recent Canadian initiative aims to improve the evidentiary basis for drug coverage...

Persistent link: https://www.econbiz.de/10005448962

Can Privatising Selected Services Benefit the Public Healthcare System?: The Greek Case

Niakas, Dimitris; Theodorou, Mamas; Liaropoulos, Lycurgus - In: Applied Health Economics and Health Policy 4 (2005) 3, pp. 153-157

The evaluation of empirical data concerning private physician consultations in public hospitals in Greece suggests that privatisation of selected public services can increase patients' freedom of choice and also improve efficiency and quality of services, thus strengthening the supply side in a...

Persistent link: https://www.econbiz.de/10005448963

Modelling the Costs and Outcomes of Changing Rates of Screening for Alcohol Misuse by GPs in the Australian Context

Shanahan, Marian; Shakeshaft, Anthony; Mattick, Richard P. - In: Applied Health Economics and Health Policy 5 (2006) 3, pp. 155-166

Aim: To assess the relative cost effectiveness of four strategies (academic detailing, computerised reminder systems, target payments and interactive continuing medical education) to increase the provision of screening and brief interventions by Australian GPs with the ultimate goal of...

Persistent link: https://www.econbiz.de/10005448964

Comparing Patient Access to Pharmaceuticals in the UK and US

Cohen, Joshua; Cairns, Catherine; Paquette, Cherie; … - In: Applied Health Economics and Health Policy 5 (2006) 3, pp. 177-187

granting of marketing authorisation. This delay was identified as the first barrier with respect to patient access to new drugs … its marketing approval date by the British Medicines Healthcare Products Agency (MHRA) or European Medicines Evaluation … Agency (EMEA). Secondly, we determined if each drug was approved by the US FDA for marketing and, if so, the date when it was …

Persistent link: https://www.econbiz.de/10005590240

How Cost-of-Illness Studies Can be Made More Useful for Illicit Drug Policy Analysis

Moore, Timothy J.; Caulkins, Jonathan P. - In: Applied Health Economics and Health Policy 5 (2006) 2, pp. 75-85

Cost-of-illness (COI) studies seemingly provide a solid foundation for quantifying the potential benefits of illicit drug policy interventions that reduce drug use at the population level. However, their usefulness is severely limited. In this paper, we suggest several improvements to substance...

Persistent link: https://www.econbiz.de/10004990314

1
2
3
4
5
6
7
8
9
10
Next
Last